⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
Health Impact Alliance Launches Life.Studio Sweden to Advance Intelligent Care and Transform Healthy Aging
businesswire.com
AMRX
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
globenewswire.com
AMRX
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
globenewswire.com
AMRX
Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer
prnewswire.com
AMRX
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
globenewswire.com
AMRX
Amneal to Participate in Upcoming Investor Conferences
globenewswire.com
AMRX
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
globenewswire.com
AMRX
Dermatomyositis Industry Intelligence Report 2025-2035 - Expanding Therapeutic Innovations and Healthcare Investments in Emerging Markets Driving Industry Growth
globenewswire.com
AMRX
RO
ENDP
HIK
JUB
MLK
Amneal Receives U.S. FDA Approval for Iohexol Injection
globenewswire.com
AMRX
Amneal Reports Third Quarter 2025 Financial Results
globenewswire.com
AMRX